Objective: Ciprofibrate (2-[4-(2,2-dichloro cyclopropyl) phenoxyl]-2-methyl propinoic acid) is a lipid-lowering drug used in the treatment of various metabolic diseases, especially hyperlipidemias. Human carbonic anhydrase II (hCA II) and glucose 6 phosphate dehydrogenase (G6PD) are crucial enzymes associated with many metabolic pathways. The aim of this study was to reveal the in vitro effect of ciprofibrate on the hydratase and esterase activities of hCAII and G6PD enzyme activity. Methods: hCA II hydratase activity was measured using the modified Wilbur-Anderson method, while esterase activity was determined using the method described by Armstrong et al. G6PD activity was determined using the Beutler method. Results: Different concentrations of ciprofibrate increased hCAII hydratase activity but exhibited no effects on hCA II esterase or G6PD activities. Conclusion: Since activation of hCA II is important in neurodegenerative diseases, such as Alzheimer's, in which carbonic anhydrase activity decreases, the use of ciprofibrate may be proposed in the treatment of such diseases. However, this now needs to be confirmed by in vivo studies. Key Words: Ciprofibrate, human carbonic anhydrase II, glucose 6 phosphate dehydrogenase Conflict of Interest: The authors have no conflict of interest.
Materials and Methods

Chemicals
The isoenzyme hCA II used to measure hydratase and esterase activities of human erythrocyte CA II was purchased from Sigma Chem. Co. (Germany), and pure G6PD enzyme was provided by the Atatürk University Chemistry Department. NADP + and glucose 6-phosphate were purchased from Sigma Chem. Co. All other chemicals used were analytical grade and purchased from either Sigma or Merck. CA II hydratase activity CA II hydratase activity was measured using the modified Wilbur-Anderson method. One enzyme unit was defined as catalytic hydration of 1 ϻmol CO 2 to HCO 3 -in 1 min. The reaction was started by the addition of 2.5 mL icecold deionized water saturated with CO 2 . The reaction tube was kept in ice to ensure a cold environment. The rate of fall in pH from 8.2 to 7.0 at 0 o C was monitored continually using a glass combination pH electrode (Hanna Instruments) connected to a digital pH meter (Hanna Instruments, HI 9321) [11] . All measurements were performed in triplicate. Briefly, 100 μL of hCA II enzyme solution and 100 μL 10% DMSO were mixed in a test tube and combined with 2.6 mL of HEPES (pH=8.80); 2.2 mL saturated CO 2 solution was then added to this mixture. For blank measurements this procedure was repeated without enzyme solution and with different concentrations of ciprofibrate. Rates of uncatalyzed CO 2 hydration were subtracted from enzyme catalyzed ones. One enzyme unit (U) of CO 2 hydratase activity was calculated using the equation EU=(t o -t c )/t c where t o and t c are the times for pH changes in non-enzymatic and enzymatic reactions, respectively. CA II esterase activity CA II esterase activity was measured using the method described by Armstrong et al. One enzyme unit of CA II esterase activity is defined as hydrolysis of 1 ϻmol pnitrophenyl acetate to p-nitrophenol and acetate in 1 min. Briefly, p-nitrophenyl acetate is hydrolyzed into p-nitrophenol and acetate by carbonic anyhdrase, and p-nitrophenol absorbance is determined spectrophotometrically at 348 nm for carbonic anhydrase esterase activity [12] . The procedure used for CA esterase activity measurement involved 1.2 mL Tris-SO 4 buffer, 0.3 mL enzyme solution and 0.3 mL pure water being mixed in a test tube. Next, 1.2 mL p-nitrophenyl acetate solution was added, and the mixture was transferred to a quartz cuvette. The absorbance was read at the end of 3 min. For blank measurements, this was repeated with different concentrations of ciprofibrate without enzyme.
Introduction
Carbonic anhydrases (CAs) are zinc-containing enzymes which catalyze CO 2 hydration, pH regulation, electrolyte secretion, ion transport, renal and male reproductive tract acidification and which exhibit wide tissue and organ distribution in the human body. To date, 13 active isoenzymes and three inactive isoforms of carbonic anhydrase (CA I-XVI) have been described in mammals. These are widely distributed in most tissues, including erythrocytes, kidney, pancreas, testes and the central nervous system. [1] . CA I and CA II co-exist in erythrocytes. CA I is the most abundant protein after hemoglobin, although CA II, the more catalytically active isoenzyme, accounts for the majority of activity in these cells [2] .
Glucose 6 phosphate dehydrogenase (D-glucose 6-phosphate: NADP + oxidoreductase EC 1.1.1.49; G6PD) is the first and key enzyme of the pentose phosphate metabolic pathway and is widespread in all tissues and blood cells, catalyzing the conversion of glucose 6-phosphate to 6-phosphoglucono-δ-lactone in the presence of nicotinamide adenine dinucleotide phosphate (NADP + ) [3] . This pathway yields NADPH and D-ribose 5-phosphate. NADPH protects the cell against oxidant agents by producing reduced glutathione [3, 4] . NADPH also participates in the synthesis of a number of biomolecules, such as fatty acids, steroids and some amino acids [5, 6] . Dribose 5-phosphate and its derivatives are components of deoxyribonucleic acid (DNA), adenosine triphosphate (ATP), coenzyme A (CoA), nicotinamide adenine dinucleotide, flavin adenine dinucleotide (FAD + ) and ribonucleic acid (RNA) [7] . NADPH deficiency leads to a decrease in the concentration of reduced glutathione in a living system, resulting in cell death. G6PD can therefore be described as an antioxidant enzyme [8] . Many drugs exhibit activating or inhibitory effects on human enzyme systems. There have been several previous studies of enzyme inhibition or activation by numerous drugs, but our scan of the literature revealed no investigations of the effects of ciprofibrate on human CA II and G6PD in vitro. Ciprofibrate is a lipid-reducing drug belonging to the class of fibrates and is used in the treatment of various metabolic diseases, especially in many hyperlipidemias. Fibrates reduce plasma triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) levels while increasing high density lipoprotein cholesterol (HDL-C) levels. They increase expression of apolipoproteinA1 (apoA1), apolipoproteinA2 (apoA2) and lipoprotein lipase (LP) and reduce apolipoproteinCIII (apoCIII), fibrinogen and plasminogen activator inhibitor-1 (PAI-1). Peroxisome proliferator-activated receptor alpha (PPARα) mediates the lipid-reducing effects of fibrates [9, 10] .
The aim of this study was to show the in vitro effect of ciprofibrate on the hydratase and esterase activities of hCA II and on G6PD activity.
Results
CA II hydratase activity was measured in all samples and was investigated 3 times on two different days. CA II hydratase activity increased proportionally to ciprofibrate concentrations, indicating that ciprofibrate acted as an activator of CA II hydratase activity (Table 1) . In term of assessment of degree of activation of ciprofibrate on CA II hydratase activity, CA hydratase activity is normally 2.85±0.90 U, and the activation degree is regarded as zero at this value. In this study, 0.05 mM ciprofibrate increased activation by 25%, a 0.10 mM concentration of ciprofibrate doubled the degree of activation and other measurements indicated that CAII activation increased proportionally to drug concentrations. However, we were unable to determine the saturation concentration of enzyme by ciprofibrate due to drug unavailability.
Effects of ciprofibrate on CA II esterase activity are shown in Table 2 . The results show that, proportional to concentration, ciprofibrate has no effect on CA II esterase activity. All investigations of CA hydratase and esterase activity were repeated three times (n=3). We attribute the different effects of ciprofibrate on hCA II hydratase and esterase activities to their different reaction mechanisms. Hydratase activity is a more commonly used method for measuring CA than esterase activity.
The effects of ciprofibrate on G6PD activity are shown in Table 3 . Enhanced ciprofibrate concentrations had no effect on enzyme activity. Ciprofibrate is therefore not correlated with G6PD and is not an activator or inhibitor for G6PD.
In conclusion, the application of various concentrations of ciprofibrate to purified enzymes increased in vitro CA II hydratase activity but did not alter esterase or G6PD enzyme activity.
Discussion
CA is a small zinc containing enzyme with a molecular weight of 30 kDA. The monomer of G6PD consists of 515 amino acids and has a molecular weight of approximately 50-60 kDa [14] [15] . Ciprofibrate is a lipid-reducing drug belonging to the class of fibrates and is used in the treatment of various metabolic diseases, especially in many hyperlipidemias.
Many drugs have adverse effects on enzymes when used for therapeutic or other purposes [16] . These effects can be dramatic and systemic [17] . Acetazolamide inhibits CA activity, giving rise to severe diuresis [18] . G6PD is affected by sodium ampicillin and netilmicin sulphate [19] , and CA is influenced by sodium ampicillin and metamizole in human red blood cells [20] .
We investigated the hydratase and esterase activity of CA II. Although the physiological function of CA II is hydration of CO 2 , the esterase activity of CA is also frequently used for the spectrophotometric determination of total CA reduction of NADP + by G6PD, in the presence of glucose 6-phosphate. One enzyme unit was defined as the reduction of 1 µmol of the NADP+/min at 37 ºC and pH=8.0 [13] . Briefly, 0.5 M 100 µL Tris buffer (pH=7.4), 100 µL 0.63 M MgCl 2 , 3.8 mM 100 µL NADP + , 50 µL enzyme solution and 550 µL pure water and 100 µL 33 mM G6P were mixed and incubated at 37 ºC for 10 min, and absorbance was read at 340 nm. This procedure was repeated with different concentrations of ciprofibrate without adding G6P. Cipro; Ciprofibrate, mM; milimolar %; percent. Enzyme activity was expressed as mean±SD, cipro was expressed as mM and activation degree was expressed as percent. Table 2 . Activation degree of ciprofibrate on CA II esterase activity. Similar to CA hydratase activity measurement all samples were studied 3 times in two different day A: Absorbance was expressed as mean±SD. Table 3 . Activation degree of ciprofibrate on G6PD activity. All values were determined 3 times, in two independent day. Activity changes were expressed as percent Enzyme activity was expressed mean±SD
Our scan of the literature revealed no previous studies investigating the effects of ciprofibrate on CA and G6PD enzyme activity. This represents the original value of the study. In this investigation, ciprofibrate solutions prepared using different concentrations increased CA hydratase activity in vitro. We hypothesized that this activation was not associated with covalent modification or genetic induction. It may be that ciprofibrate can cause in vitro activation of CA by binding metal ions. In our study, the highest ciprofibrate concentration, 0.20 mM, was prepared with a 34.5 mM stock ciprofibrate concentration. A 0.20 mM ciprofibrate solution is suitable for in vivo studies.
In conclusion, ciprofibrate is a lipid-reducing drug that increases CA hydratase activity in a dose-dependent manner. The highest concentration of ciprofibrate (0.2 mM) used in the study is easily available. This may suggest that in addition to improving the lipid profile in individuals using this drug, its use may also increase CA activity in the presence of a neurodegenerative disease such as Alzheimer's in which CA activity decreases. We also established that ciprofibrate did not alter CA esterase or G6PD activity at different concentrations.
activities in the enzyme purification steps. Our scan of the literature revealed no studies confirming this behavior of ciprofibrate. However, some studies have shown that ciprofibrate inhibits aldose reductase enzyme activity in a concentration-dependent manner [21] . Recent studies have reported a decrease in neuronal CA activity in some cases of neurodegenerative diseases, such as Alzheimer's. For this reason, the use of CA activators to compensate for this decline has been proposed in the treatment of the disease. Since ciprofibrate is used in the treatment of hyperlipidemia, it may make a significant positive contribution in patients with neurodegeneration. Various studies have also investigated the effect of different drugs on G6PD enzyme activity. One study involving catechin pre-treatment reported an improvement in the level of cytochrome P450 (CYP-450) content and in the activities of glutathione metabolizing enzymes, glutathione-S-transferase (GST), glutathione reductase (GR) and glutathione peroxidase (GPx), and other antioxidant enzymes, such as G6PD, catalase (CAT) and superoxide dismutase (SOD), in both liver and kidney compared to tamoxifen-treated animals [22] . In an in vivo study, Parvez et al. demonstrated that antioxidant enzyme activity increased with the application of specific concentrations of catechin compared with tamoxifen. In another study, lipid peroxidation, protein carbonyl and H 2 O 2 content decreased with resveratrol therapy, while G6PD, serum lactate dehydrogenase (LDH) and mitochondrial glutathione content increased [23] . Similarly, we used different concentrations of ciprofibrate to investigate the effects on hydratase and esterase activities of human carbonic anhydrase II (hCA II) and on human glucose 6 phosphate dehydrogenase (G6PD) activity. Hydratase activity increased in proportion to concentration, while G6PD activity and CA esterase remained unchanged. The application of specific concentrations of ciprofibrate also had no effect on G6PD enzyme activity.
Numerous in vitro and in vivo studies have investigated the effect of ciprofibrate on enzyme activities [24] [25] [26] [27] . Goll et al. applied ciprofibrate and its species at varying concentrations (100-500 mM) to rat hepatocyte culture for 72 hours and reported an increase in the activities of mitochondrial enzymes (acyl CoA oxidase (ACO) and carnitine acetyl transferase (CAT)) [24] . Another study showed that ciprofibrate stimulated protein kinase C-dependent phosphorylation in rat Fao hepatic derived cells, and that this is important for signal transmission [25] . Paragh et al.
reported that ciprofibrate increased paraoxonase activity in patients with metabolic syndrome [26] . The enzymespecific effect of ciprofibrate on 3-hydroxy steroid dehydrogenase-isomerase (3-HSD) in the testes, a tissuespecific effect, was also evident since no significant effects of ciprofibrate were reported in the activities of 3-HSD or Steroid 21-hydroxylase (21-OHase) in the adrenal glands of the same animals [27] . In the light of these studies, we wished to observe the in vitro effect of ciprofibrate on human carbonic anhydrase II and G6PD activities.
